Connective Capital Management’s CervoMed CRVO Stock Holding History

Connective Capital Management’s Portfolio CRVO Stock Details CRVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1	Closed	-$5	–	41
2022 Q4	$5	Buy	+1	New	+$8	﹤0.01%	55

Other funds holding CRVO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Connective Capital Management's CRVO Position: Q1 2023 in Review

Connective Capital Management sold out of CervoMed (CRVO) in Q1 2023, closing a stake of 1 share — an estimated $5 sold.

Connective Capital Management first reported a position in CRVO in Q4 2022 and held it in 1 quarter. The position peaked at $5 in Q4 2022. 12 funds tracked by Wall St. Rank hold CRVO as of Q1 2023.

Connective Capital Management reported no remaining CervoMed position as of Q1 2023 after selling out during the quarter.
Connective Capital Management sold 1 CervoMed share in Q1 2023, an estimated $5.
Connective Capital Management first reported a position in CervoMed in Q4 2022 and held it in 1 quarter.
Connective Capital Management's CervoMed position peaked at $5 in Q4 2022.
12 funds tracked by Wall St. Rank held CervoMed as of Q1 2023.

Based on Connective Capital Management's 13F filing for Q1 2023, filed 17 May 2024.